Skip to main content
SpringerLink
Log in
Birkhäuser

ACE Inhibitors

  • Book
  • © 2001

Overview

Editors:
  1. Pedro D’Orléans-Juste

    1. Department of Pharmacology, Institute of Pharmacology of Sherbrooke, Medical School, Sherbrooke University, Sherbrooke, Canada

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Gérard E. Plante

    1. Department of Pharmacology, Institute of Pharmacology of Sherbrooke, Medical School, Sherbrooke University, Sherbrooke, Canada
      Departments of Medicine (Nephrology), Physiology and Pharmacology, Institute of Pharmacology, University of Sherbrooke, Sherbrooke, Canada

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Milestones in Drug Therapy (MDT)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (14 chapters)

  1. Front Matter

    Pages I-X
    Download chapter PDF

  2. The history of inhibitors of angiotensin converting enzyme

    • John R. Vane
    Pages 1-10

  3. Genetics of the renin-angiotensin-aldosterone system and risk of arterial disease

    • Malika Lajemi, Athanase Benetos
    Pages 11-27

  4. Crosstalk between ACE inhibitors, B2 kinin receptor and nitric oxide in endothelial cells

    • Paulus Wohlfart, Gabriele Wiemer, Wolfgang Linz, Bernward A. Schölkens
    Pages 29-36

  5. Interactions between the ACE and the endothelin pathway

    • Rob L. Hopfner, J. Robert McNeill, Venkat Gopalakrishnan
    Pages 37-45

  6. Evaluative and epidemiological approaches of ACE therapy

    • Maxime Lamarre-Cliche, Pierre Larochelle
    Pages 47-70

  7. The role of ACE inhibition in heart failure

    • Irene Gavras, Haralambos Gavras
    Pages 71-79

  8. Angiotensin converting enzyme inhibition in the microcirculation

    • Gérard E. Plante, Tewfik Nawar
    Pages 81-103

  9. Arterial structure and function and blockade of the renin-angiotensin system in hypertension

    • Michel E. Safar, Harry A. J. Struijker Boudier, Luc M. A. B. Van Bortel, Gérard M. London
    Pages 105-127

  10. The contribution of angiotensin-converting enzyme (ACE) to the metabolism of kinins (bradykinin and des-Arg9-bradykinin) and effect of ACE inhibitors on their in vitro and in vivo metabolism

    • Albert Adam, Charles Blais Jr., François Marceau
    Pages 129-144

  11. Role of the renin-angiotensin system on the central and peripheral autonomic nervous system

    • Jacques de Champlain, Pedro D’Orléans-Juste
    Pages 145-153

  12. Dual inhibitors of angiotensin converting enzyme and neutral endopeptidase

    • Cynthia A. Fink
    Pages 155-162

  13. Pharmacodynamics, tissue-specificity of ACE inhibitors

    • Stylianos E. Orfanos, Linhua Zou, John D. Catravas
    Pages 163-170

  14. Effect of angiotensin converting enzyme inhibition on thirst and salt-appetite

    • Tewfik Nawar, Eve-Reine Gagné, Raymonde Turcotte, Gérard E. Plante
    Pages 171-176

  15. ACE and diabetes

    • Mark E. Cooper
    Pages 177-184

  16. Back Matter

    Pages 185-187
    Download chapter PDF
Back to top

Keywords

About this book

Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis­ order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun­ tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop­ ment almost failed when serious side-effects were reported in an alarmist fash­ ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar­ macological actions.

Editors and Affiliations

  • Department of Pharmacology, Institute of Pharmacology of Sherbrooke, Medical School, Sherbrooke University, Sherbrooke, Canada

    Pedro D’Orléans-Juste, Gérard E. Plante

  • Departments of Medicine (Nephrology), Physiology and Pharmacology, Institute of Pharmacology, University of Sherbrooke, Sherbrooke, Canada

    Gérard E. Plante

Bibliographic Information

  • Book Title: ACE Inhibitors

  • Editors: Pedro D’Orléans-Juste, Gérard E. Plante

  • Series Title: Milestones in Drug Therapy

  • DOI: https://doi.org/10.1007/978-3-0348-7579-0

  • Publisher: Birkhäuser Basel

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Basel AG 2001

  • Softcover ISBN: 978-3-0348-7581-3Published: 18 September 2012

  • eBook ISBN: 978-3-0348-7579-0Published: 06 December 2012

  • Series ISSN: 2296-6056

  • Series E-ISSN: 2296-6064

  • Edition Number: 1

  • Number of Pages: X, 187

  • Number of Illustrations: 24 b/w illustrations

  • Topics: Medicine/Public Health, general

Publish with us

Policies and ethics

Back to top

Search

Navigation